Biomarin Pharmaceutical Inc (NASDAQ: BMRN) is -11.35% lower on its value in year-to-date trading and has touched a low of $52.93 and a high of $94.85 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BMRN stock was last observed hovering at around $58.70 in the last trading session, with the day’s loss setting it -0.43%.
Currently trading at $58.27, the stock is -4.46% and -9.90% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.29 million and changing -0.73% at the moment leaves the stock -16.45% off its SMA200. BMRN registered -27.61% loss for a year compared to 6-month loss of -12.20%.
The stock witnessed a -2.92% gain in the last 1 month and extending the period to 3 months gives it a -9.55%, and is -2.59% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.16% over the week and 3.21% over the month.
Biomarin Pharmaceutical Inc (BMRN) has around 3040 employees, a market worth around $11.17B and $2.92B in sales. Current P/E ratio is 21.62 and Fwd P/E is 13.37. Profit margin for the company is 17.93%. Distance from 52-week low is 10.09% and -38.57% from its 52-week high. The company has generated returns on investments over the last 12 months (8.20%).
The EPS is expected to grow by 58.11% this year
The shares outstanding are 191.76M, and float is at 188.20M with Short Float at 2.39%.
The top institutional shareholder in the company is BLACKROCK INC. with over 22.74 million shares valued at $1.87 billion. The investor’s holdings represent 11.9604 of the BMRN Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 18.99 million shares valued at $1.56 billion to account for 9.9909 of the shares outstanding. The other top investors are PRIMECAP MANAGEMENT CO/CA/ which holds 18.79 million shares representing 9.8836 and valued at over $1.55 billion, while DODGE & COX holds 7.3274 of the shares totaling 13.93 million with a market value of $1.15 billion.
Biomarin Pharmaceutical Inc (BMRN) Insider Activity
The most recent transaction is an insider sale by Hubbard Cristin, the company’s EVP, Chief Commercial Officer. SEC filings show that Hubbard Cristin sold 273 shares of the company’s common stock on May 02 ’25 at a price of $64.92 per share for a total of $17723.0. Following the sale, the insider now owns 32700.0 shares.
Still, SEC filings show that on Mar 19 ’25, Burkhart Erin (GVP, Chief Accounting Officer) disposed off 1,295 shares at an average price of $71.52 for $92618.0. The insider now directly holds 16,955 shares of Biomarin Pharmaceutical Inc (BMRN).
